Divya Dahiya
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Divya Dahiya has a total of 30 co-authors. Here are the top co-authors by number of shared publications:
- Sanjay Kumar Bhadada
Department of Endocrinology, Postgraduate Institute of Medical Education and Research (PGIMER), Chandigarh, India
3 shared publications - Uma Nahar Saikia
Department of Histopathology Postgraduate Institute of Medical Education and Research Chandigarh India
2 shared publications Anoop Kumar
Department of Dermatology, Postgraduate Institute of Medical Education and Research , Chandigarh 160012
1 shared publicationApurva Sood
1 shared publication- Arunanshu Behera
Clinic of General and Laparoscopic Surgery, Livasa Hospitals, Mohali, India
1 shared publication Ashutosh Kumar Arya
Department of Endocrinology & Metabolism, All India Institute of Medical Sciences , New Delhi 110029
1 shared publication
Latest Publications
- 26 August 2026
- Published by Elsevier in Annals of Diagnostic Pathology
- Vol. 86
Clinicopathological predictors of radioiodine response in differentiated high-grade thyroid carcinoma
- 26 August 2026
- Published by Elsevier in Annals of Diagnostic Pathology
- Vol. 86
Clinicopathological predictors of radioiodine response in differentiated high-grade thyroid carcinoma
- 3 June 2026
- Published by Springer Nature in Annals of Nuclear Medicine
- Vol. 40 (10) , 1229-1236
Efficacy and safety of peptide receptor radionuclide therapy in advanced foregut and hindgut neuroendocrine tumors: a real-world experience from a single institution
Foregut and hindgut neuroendocrine tumors (NETs) contribute significantly to the global NET burden especially in Asian population; however, these cohorts are sparse and underrepresented in current trials assessing peptide receptor radionuclide therapy (PRRT) in gastroenteropancreatic (GEP) NETs. This single-centre study evaluates the efficacy and safety of PRRT in advanced foregut and hindgut NETs. Retrospective data evaluation of consecutive patients with biopsy-proven metastatic foregut (gastric, lung and thymic NETs) and hindgut NETs (colorectal, anal and sacral NETs) who underwent PRRT from 2014 to 2024 at a tertiary care hospital was done. Up to four cycles of 177Lu-DOTATATE (7.4 GBq/cycle) were administered intravenously every 6-8 weeks along with nephroprotection. Interim and end-of-treatment 68Ga-DOTANOC PET/CT scans were acquired for response evaluation, based on RECIST v1.1. Objective response rate (ORR), disease control rate (DCR), best biochemical response, toxicity profile, quality-of-life scores, progression-free survival (PFS) and overall survival (OS) were assessed. Thirty-four patients (median age-56 yrs) with foregut (n = 16) and hindgut (n = 18) NETs received a total of 111 cycles (range 1-4) of 177Lu-DOTATATE (median cumulative activity 26.5 GBq). The best ORR and DCR were 45% and 80%, median PFS was 29.7 months (95% CI, 20.3-39.1), and the 1- and 5-year OS rates were 93.8% (95% CI, 85.4-100) & 53.6% (95% CI, 28.6-78.6), respectively, after a median follow-up of 45.3 months. Grade 3 adverse events were observed in only five patients. PRRT appears to be safe and effective treatment modality in advanced foregut and hindgut NETs. More prospective trials are required to validate these findings in larger cohorts.
- 3 June 2026
- Published by Springer Nature in Annals of Nuclear Medicine
- Vol. 40 (10) , 1229-1236
Efficacy and safety of peptide receptor radionuclide therapy in advanced foregut and hindgut neuroendocrine tumors: a real-world experience from a single institution
Foregut and hindgut neuroendocrine tumors (NETs) contribute significantly to the global NET burden especially in Asian population; however, these cohorts are sparse and underrepresented in current trials assessing peptide receptor radionuclide therapy (PRRT) in gastroenteropancreatic (GEP) NETs. This single-centre study evaluates the efficacy and safety of PRRT in advanced foregut and hindgut NETs. Retrospective data evaluation of consecutive patients with biopsy-proven metastatic foregut (gastric, lung and thymic NETs) and hindgut NETs (colorectal, anal and sacral NETs) who underwent PRRT from 2014 to 2024 at a tertiary care hospital was done. Up to four cycles of 177Lu-DOTATATE (7.4 GBq/cycle) were administered intravenously every 6-8 weeks along with nephroprotection. Interim and end-of-treatment 68Ga-DOTANOC PET/CT scans were acquired for response evaluation, based on RECIST v1.1. Objective response rate (ORR), disease control rate (DCR), best biochemical response, toxicity profile, quality-of-life scores, progression-free survival (PFS) and overall survival (OS) were assessed. Thirty-four patients (median age-56 yrs) with foregut (n = 16) and hindgut (n = 18) NETs received a total of 111 cycles (range 1-4) of 177Lu-DOTATATE (median cumulative activity 26.5 GBq). The best ORR and DCR were 45% and 80%, median PFS was 29.7 months (95% CI, 20.3-39.1), and the 1- and 5-year OS rates were 93.8% (95% CI, 85.4-100) & 53.6% (95% CI, 28.6-78.6), respectively, after a median follow-up of 45.3 months. Grade 3 adverse events were observed in only five patients. PRRT appears to be safe and effective treatment modality in advanced foregut and hindgut NETs. More prospective trials are required to validate these findings in larger cohorts.
- 15 December 2025
- Published by The Endocrine Society in The Journal of Clinical Endocrinology & Metabolism
- Vol. 111 (6) , 1680-1691
Aberrant Histone Methylation Profile in Patients with Sporadic Primary Hyperparathyroidism
Introduction: Primary hyperparathyroidism (PHPT) is a systemic endocrine disorder characterized by elevated PTH levels and hypercalcemia. Gene-specific epigenetic modifications like histone methylation play a pivotal role in PHPT by altering expression of parathyroid-specific genes. However, global histone modifications in parathyroid tumors and their implications for tumor behavior remain underexplored. Experimental Design: We performed comparative histone modification profiling in blood and tissue samples from sporadic parathyroid adenomas (PA; n = 30), atypical parathyroid tumors (APT; n = 05), and parathyroid carcinomas (PC; n = 05) along with controls using histone H3 multiplex immunoassay. Significantly dysregulated modifications were validated by Western blotting (WB), and expression data was correlated with clinicopathological features. We performed pathway enrichment analysis to elucidate molecular pathways potentially linked to histone H3 modifications in parathyroid tumorigenesis. Results: We observed dynamic alterations in histone H3 modifications of lysine (K) residues across parathyroid tumor phenotypes in blood and tissue samples. A reduction in H3K4 and H3K36 trimethylation (130%) compared to controls was observed. WB confirmed lower H3K4me3 (0.5 ± 0.4 vs 4.4 ± 0.7, P = .02; 0.4 ± 0.2 vs 4.4 ± 0.7, P = .004) and H3K36me3 (0.4 ± 0.2 vs 1.0 ± 0.3, P = .03; 0.2 ± 0.1 vs 1.0 ± 0.3, P = .02) in APT and PC than controls and higher H3K27me3 expression in PA (2.9 ± 1.2 vs 1.1 ± 0.21, P = .04), APT (4.2 ± 2.9 vs 1.1 ± 0.21, P = .007), and PC (6.9 ± 3.1 vs 1.1 ± 0.21, P = .0002) relative to controls. Pathway enrichment analysis identified molecular pathways, including calcium signaling, Wnt, and Hippo signaling, associated with histone H3 modifications. Conclusion: Increased expression of repressive H3K27me3 in blood and tissue samples, while decreased H3K4me3 and H3K36me3, suggest a shift toward transcriptional repression. Identifying their functional mechanisms may facilitate the discovery of novel insights for therapeutic targeting in parathyroid tumors.
- 15 December 2025
- Published by The Endocrine Society in The Journal of Clinical Endocrinology & Metabolism
- Vol. 111 (6) , 1680-1691
Aberrant Histone Methylation Profile in Patients with Sporadic Primary Hyperparathyroidism
Introduction: Primary hyperparathyroidism (PHPT) is a systemic endocrine disorder characterized by elevated PTH levels and hypercalcemia. Gene-specific epigenetic modifications like histone methylation play a pivotal role in PHPT by altering expression of parathyroid-specific genes. However, global histone modifications in parathyroid tumors and their implications for tumor behavior remain underexplored. Experimental Design: We performed comparative histone modification profiling in blood and tissue samples from sporadic parathyroid adenomas (PA; n = 30), atypical parathyroid tumors (APT; n = 05), and parathyroid carcinomas (PC; n = 05) along with controls using histone H3 multiplex immunoassay. Significantly dysregulated modifications were validated by Western blotting (WB), and expression data was correlated with clinicopathological features. We performed pathway enrichment analysis to elucidate molecular pathways potentially linked to histone H3 modifications in parathyroid tumorigenesis. Results: We observed dynamic alterations in histone H3 modifications of lysine (K) residues across parathyroid tumor phenotypes in blood and tissue samples. A reduction in H3K4 and H3K36 trimethylation (130%) compared to controls was observed. WB confirmed lower H3K4me3 (0.5 ± 0.4 vs 4.4 ± 0.7, P = .02; 0.4 ± 0.2 vs 4.4 ± 0.7, P = .004) and H3K36me3 (0.4 ± 0.2 vs 1.0 ± 0.3, P = .03; 0.2 ± 0.1 vs 1.0 ± 0.3, P = .02) in APT and PC than controls and higher H3K27me3 expression in PA (2.9 ± 1.2 vs 1.1 ± 0.21, P = .04), APT (4.2 ± 2.9 vs 1.1 ± 0.21, P = .007), and PC (6.9 ± 3.1 vs 1.1 ± 0.21, P = .0002) relative to controls. Pathway enrichment analysis identified molecular pathways, including calcium signaling, Wnt, and Hippo signaling, associated with histone H3 modifications. Conclusion: Increased expression of repressive H3K27me3 in blood and tissue samples, while decreased H3K4me3 and H3K36me3, suggest a shift toward transcriptional repression. Identifying their functional mechanisms may facilitate the discovery of novel insights for therapeutic targeting in parathyroid tumors.
- Open Access
- 4 July 2025
- Published by Galenos Yayinevi in Turkish Journal of Surgery
- Vol. 41 (3) , 235-240
Evaluation of quality of life in primary hyperparathyroidism patients: Pre- and post-parathyroidectomy outcomes in an Indian cohort
Evaluation of quality of life in primary hyperparathyroidism patients: Pre- and post-parathyroidectomy outcomes in an Indian cohort - Turkish Journal of Surgery
- 4 July 2025
- Published by Galenos Yayinevi in Turkish Journal of Surgery
- Vol. 41 (3) , 235-240
Open AccessEvaluation of quality of life in primary hyperparathyroidism patients: Pre- and post-parathyroidectomy outcomes in an Indian cohort
Evaluation of quality of life in primary hyperparathyroidism patients: Pre- and post-parathyroidectomy outcomes in an Indian cohort - Turkish Journal of Surgery